Meridian Bioscience Reiterates FY14 Guidance; Sees "Modest" Growth In FY15

(RTTNews) - Diagnostic test kits maker Meridian Bioscience, Inc. (VIVO) Tuesday confirmed its annual outlook and set "modest" revenue and profit growth targets for fiscal 2015.

In addition, Executive Chairman, William Motto, said the management will be recommending to the board that the indicated annual dividend rate of $0.80 be maintained.

Meridian continues to expect fiscal 2014 earnings of $0.85 and $0.90 per share on revenues of $190 million to $195 million.

For fiscal 2015, the company expects earnings of $0.85 and $0.91 per share on revenues of $193 million to $200 million, with its projections at this time being close to the low end of the guidance range.